MorphoSys To Release Myelofibrosis Trial Data This Year

Shares of MorphoSys AG (MOR), which have been experiencing strong momentum this year, touched a new 52-week high of $6.85 during intraday trading yesterday..

Related Keywords

China ,Spain ,Japan ,Germany ,Italy ,France ,United Kingdom ,Lenalidomide Revlimid ,Incyte Jakafi ,Incyte Corp ,Nasdaq Global Market ,Fda ,Myelofibrosis ,Revlimid ,Blood Cancer ,Bone Marrow ,Morphosys ,Monjuvi ,